|
www.aurobindo.com |
|
|
Hyderabad, 19th July, 2005 |
|
|
|
AUROBINDO GETS EDQM APPROVAL FOR
DOMPERIDONE & DOMPERIDONE MALEATE |
|
|
|
Aurobindo Pharma
Limited (Reuters Code:
ARBN.BO) is pleased to announce that it
has been granted the Certificate of Suitability
of monographs of the European Pharmacopoeia by
the European Directorate for the Quality of
Medicines (EDQM) for its Active Pharmaceutical
Ingredients (API) Domperidone and Domperidone
Maleate.
|
|
Domperidone is a
commonly used product in gastrointestinal
disorders like vomiting. Aurobindo Pharma
Limited has started receiving approvals to
penetrate the European market. Aurobindo has
filed several DMFs/CoS/Formulation dossiers with
various applicable authorities in Europe for its
product range. With the endorsement from
European Directorate for the Quality of
Medicines (EDQM), Aurobindo Pharma Limited will
be able to sell the above products in whole of
Europe.
|
|
|
|
About Aurobindo Pharma Limited |
|
Aurobindo Pharma
Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. Aurobindo Pharma is
a vertically integrated at mega scale with
proven capabilities in chemical, formulation
research and manufacturing of sterile and oral
immediate release and specialty dosage
formulations. Over 500 scientists drive the
research efforts of Aurobindo. Six independent
facilities for APIs and four formulation
facilities support the efforts of Aurobindo in
entering the regulated market. The company has
received approvals for several facilities
manufacturing APIs and formulations from leading
regulatory agencies like US FDA, UK MHRA, WHO,
Health Canada, MCC South Africa, Anvisa Brazil.
The company’s robust product portfolio is spread
over 6 major therapeutic/product areas
encompassing (Antibiotics, Anti-Retrovirals,
CVS, CNS, Gastroenterologicals, and Anti-Allergics)
around 65 APIs in the non-antibiotics and 55
APIs in the antibiotic segment. The company is
marketing these products globally, in over 100
countries. The company markets its
APIs/formulations to generic/branded MNCs,
pharmaceutical wholesalers,
hospitals/institutions and governments across
the world. |
|
|
|
|
|
PRESS
ROOM
